The Law Firm of Alonso Krangle LLP Now Evaluating Actos Lawsuit Claims on Behalf of Victims of Actos Bladder Cancer …

Alonso Krangle LLP is now evaluating lawsuits on behalf of Actos side effect victims who have been diagnosed with bladder cancer that may be related to their use of Actos. The U.S. Food & Drug Administration (FDA) warned last year that use of Actos may increase the risk of bladder cancer in people who use the type 2 diabetes medication for more than one year.

Melville, NY (PRWEB) March 06, 2012

Actos Lawsuit Claims and What to Do

Alonso Krangle LLP is now offering free Actos lawsuit evaluations to anyone who believes they developed bladder cancer side effects because of Actos or a related drug, including Actoplus Met, Actoplus Met XR and Duetact. To discuss a potential Actos bladder cancer lawsuit claim with one of the experienced and compassionate Actos lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

Actos Bladder Cancer Side Effects

Actos, known generically as pioglitazone, is an oral diabetes medication marketed by Takeda Pharmaceuticals. Actos was approved by the U.S. Food & Drug Administration (FDA) in 1999, and has since become the best-selling type 2 diabetes medications in the world. [bloomberg.com/news/2011-12-31/takeda-suits-on-actos-diabetes-drug-combined-in-one-louisiana-court.html]. Pioglitazone, the active ingredient in Actos is also sold in combination with metformin (Actoplus Met, Actoplus Met XR) and glimepiride (Duetact).

In June 2011, the FDA warned that patients taking Actos for more than one year may be at an increased risk of developing bladder cancer. The warning was based on the agencys review of data from a planned five-year interim analysis of an ongoing, ten-year epidemiological study. According to the FDA, compared to never being exposed to pioglitazone, a duration of pioglitazone therapy longer than 12 months was associated with a 40% increase in risk of developing bladder cancer. The findings prompted the FDA to add information about bladder cancer to the Warnings and Precautions section of the label for pioglitazone-containing medicines, including Actos. The patient Medication Guide for pioglitazone-containing medicines was also revised to include information on the risk of bladder cancer. [fda.gov/Drugs/DrugSafety/ucm259150.htm]

Actos users from around the country who have been diagnosed with bladder cancer are now filing lawsuits alleging Takeda Pharmaceuticals failed to adequately warn patients and doctors about the drugs association with bladder cancer. Late last year, the U.S. Judicial Panel on Multidistrict Litigation ordered that all Actos bladder cancer lawsuits filed in federal courts throughout the U.S. be consolidated in a multidistrict litigation and transferred to U.S. District Court for the Western District of Louisiana, in Lafayette, to be overseen by U.S. District Judge Rebecca Doherty (MDL 2299). [lawd.uscourts.gov/MDL2299/11-md-2299.122911.transferorder1.pdf] In an order dated February 13, 2012, Judge Doherty set the first status conference in the Actos bladder cancer litigation for March 22, 2012.[lawd.uscourts.gov/MDL2299/11-md-2299.o.tzd.pdf ]

Alonso Krangle LLP is now offering free legal evaluations to anyone who believes they developed bladder cancer because of Actos. To discuss a potential Actos bladder cancer lawsuit claim with one of the experienced and compassionate defective drug lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

About Alonso Krangle LLP

Continued here:
The Law Firm of Alonso Krangle LLP Now Evaluating Actos Lawsuit Claims on Behalf of Victims of Actos Bladder Cancer ...